Myocardial interstitial fibrosis and diastolic dysfunction in hypertrophic cardiomyopathy;Fibrosi interstiziale miocardica e disfunzione diastolica nella cardiomiopatia ipertrofica

Italian Heart Journal, Supplementi

Volumn 4, Issue 8, 2003, Pages 645-650

  Lombardi, Raffaella ^a   Betocchi, Sandro ^a   Cacace, Alessandra ^a   Losi, Maria Angela ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Collagen; Diastolic dysfunction; Hypertrophic cardiomyopathy

Indexed keywords

EID: 77957107839     PISSN: 15903796     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Maron BJ, Bonow RO, Cannon RO, Leon MB, Epstein SE. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med 1987; 316: 780-844.
2. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 2001; 33: 655-70. (Pubitemid 32538979)
3. Watkins H, Seidman CE, Seidman JG, Feng HS, Sweeney HL. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence of a dominant negative action. J Clin Invest 1996; 98: 2456-61. (Pubitemid 26415065)
4. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355: 58-60.
5. Cuda G, Fananapazir L, Zhu WS, Sellers JR, Epstein ND. Skeletal muscle expression and abnormal function of beta-myosin in hypertrophic cardiomyopathy. J Clin Invest 1993; 91: 2861-5. (Pubitemid 23182546)
6. Marian AJ, Zhao G, Seta Y, Roberts R, Yu QT. Expression of a mutant (Arg92 Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. Circ Res 1997; 81: 76-85. (Pubitemid 27272985)
7. Nagueh S, Stetson SJ, Lakkis NM, et al. Decreased expression of tumor necrosis factor-α and regression of hypertrophy after non-surgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation 2001; 103: 1844-50.
8. Hasegawa K, Fujiwara H, Koshiji M, et al. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 1996; 27: 259-64.
9. 1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997; 96: 874-81.
10. Briguori C, Betocchi S, Manganelli F, et al. Determinants and clinical significance of natriuretic peptides in hypertrophic cardiomyopathy. Eur Heart J 2001; 22: 1328-36.
11. Lim DS, Roberts R, Marian AJ. Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J Am Coll Cardiol 2001; 38: 1175-80. (Pubitemid 32912729)
12. Lechin M, Quinones MA, Omran A, et al. Angiotensin-I converting enzyme genotypes and left ventricular hypertrophy in patients with hypertrophic cardiomyopathy. Circulation 1995; 92: 1808-12.
13. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993; 342: 1085-6. (Pubitemid 23338741)
14. Patel R, Lim DS, Reddy D, et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000; 32: 2369-77.
15. Gwathmey JK, Warren SE, Briggs GM, et al. Diastolic dysfunction in hypertrophic cardiomyopathy; effect on active force generation during systole. J Clin Invest 1991; 87: 1023-31.
16. Betocchi S, Hess OM, Losi MA, Nonogi H, Krayenbuehl HP. Regional left ventricular mechanics in hypertrophic cardiomyopathy. Circulation 1993; 88: 2206-19.
17. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and diastolic filling abnormalities in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990; 15: 808-13. (Pubitemid 20101571)
18. Nagueh SF, Lakkis NM, Middleton KJ, Spencer WH, Zoghbi WA, Quinones MA. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999; 99: 254-61.
19. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kaway C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55: 575-81. (Pubitemid 16092908)
20. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35: 36-44. (Pubitemid 30061256)
21. Pardo-Mindan JF, Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J 1993; 14 (Suppl J): 12-4. (Pubitemid 23355384)
22. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000; 84: 476-82.
23. Briguori C, Betocchi S, Romano M, et al. Exercise capacity in hypertrophic cardiomyopathy depends on left ventricular diastolic function. Am J Cardiol 1999; 84: 309-15.
24. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103: 789-91.
25. Kawano H, Do YS, Kawano Y, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101: 1130-7. (Pubitemid 30146614)
26. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104: 317-24.
27. Diez J, Laviades C, Mayor G, et al. Increased serum concentration of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995; 91: 1450-6.
28. Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-8.
29. Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002; 105: 2512-7. (Pubitemid 34568973)
30. Querejeta R, Varo N, Lopez B, et al. Serum carboxy-terminal propeptide of collagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000; 101: 1729-35.
31. Lopez B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-91. (Pubitemid 32666949)
32. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-93.
33. Wilson JM, Villareal RP, Hariharan R, Massumi A, Muthupillai R, Flamm SD. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. Tex Heart Inst J 2002; 29: 176-80. (Pubitemid 35006923)
34. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-7.
35. Diez J, Laviades C. Monitoring fibrillar collagen turnover in hypertensive heart disease. Review. Cardiovasc Res 1997; 35: 202-5. (Pubitemid 27372031)
36. Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000; 46: 214-24.
37. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation 2000; 102: 2700-6.
38. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997; 35: 30-4.
39. Lombardi R, Betocchi S, Losi MA, et al. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circulation, in press.
40. Lombardi R, Aversa M, Losi MA, et al. Myocardial collagen turnover affects diastolic function in hypertrophic cardiomyopathy. (abstr) Circulation 2002; 106: II-711.
41. Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 1989; 79: 744-55. (Pubitemid 19100533)